Search - tctmd.com

Displaying 121 - 140 of 752

Sort: Relevancy | Date

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

News Daily News

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

December 02, 2019

Long-term Watchman Data Reassure: CAP and CAP2 Registries

News Daily News

Long-term Watchman Data Reassure: CAP and CAP2 Registries

Michael O'Riordan

December 02, 2019

Dabigatran Discontinuation Rate Highest Early After Treatment Begins

News Daily News

Dabigatran Discontinuation Rate Highest Early After Treatment Begins

November 12, 2019

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

News Daily News

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

November 01, 2019

Anticoagulant Type May Influence Fracture Risk in A-fib Patients

News Daily News

Anticoagulant Type May Influence Fracture Risk in A-fib Patients

October 21, 2019

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

News Daily News

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

October 15, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

September 29, 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presentation TCT 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presenter: Teresa Carman

September 27, 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

News Daily News

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

July 23, 2019

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

News Features

Anticoagulation On Demand? The Pill-in-the-Pocket Approach to A-fib Treatment

June 25, 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Don’t Stop The Warfarin!: A Case of Left Atrial Appendage Closure Device Thrombus

Presentation TVT 2019

Don’t Stop The Warfarin!: A Case of Left Atrial Appendage Closure Device Thrombus

Presenter: Siri Kadire

June 13, 2019

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Presentation TVT 2019

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Presenter: DJ Lakkireddy

June 13, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.